9
IRUS Total
Downloads
  Altmetric

β-synuclein potentiates synaptic vesicle dopamine uptake and rescues dopaminergic neurons from MPTP-induced death in the absence of other synucleins.

File Description SizeFormat 
1-s2.0-S0021925821011819-main.pdfPublished version1.69 MBAdobe PDFView/Open
Title: β-synuclein potentiates synaptic vesicle dopamine uptake and rescues dopaminergic neurons from MPTP-induced death in the absence of other synucleins.
Authors: Ninkina, N
Millership, SJ
Peters, OM
Connor-Robson, N
Chaprov, K
Kopylov, AT
Montoya, A
Kramer, H
Withers, DJ
Buchman, VL
Item Type: Journal Article
Abstract: Synucleins, a family of three proteins highly expressed in neurons, are predominantly known for the direct involvement of α-synuclein in the aetiology and pathogenesis of Parkinson's and certain other neurodegenerative diseases, but their precise physiological functions are still not fully understood. Previous studies have demonstrated the importance of α-synuclein as a modulator of various mechanisms implicated in chemical neurotransmission, but information concerning the involvement of other synuclein family members, β-synuclein and γ-synuclein, in molecular processes within presynaptic terminals is limited. Here we demonstrated that the vesicular monoamine transporter 2 (VMAT2)-dependent dopamine uptake by synaptic vesicles isolated from the striatum of mice lacking β-synuclein is significantly reduced. Reciprocally, reintroduction, either in vivo or in vitro, of β-synuclein but not α- or γ-synuclein improves uptake by triple α/β/γ-synuclein deficient striatal vesicles. We also showed that the resistance of dopaminergic neurons of the substantia nigra pars compacta (SNpc) to subchronic administration of the Parkinson's disease-inducing prodrug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) depends on the presence of β-synuclein but only when one or both other synucleins are absent. Furthermore, proteomic analysis of synuclein-deficient synaptic vesicles vs those containing only β-synuclein revealed differences in their protein compositions. We suggest that the observed potentiation of dopamine uptake by β-synuclein might be caused by different protein architecture of the synaptic vesicles. It is also feasible that such structural changes improve synaptic vesicle sequestration of 1-methyl-4-phenylpyridinium (MPP+), a toxic metabolite of MPTP, which would explain why dopaminergic neurons expressing β-synuclein and lacking α-synuclein and/or γ-synuclein are resistant to this neurotoxin.
Issue Date: Dec-2021
Date of Acceptance: 28-Oct-2021
URI: http://hdl.handle.net/10044/1/92795
DOI: 10.1016/j.jbc.2021.101375
ISSN: 0021-9258
Publisher: American Society for Biochemistry and Molecular Biology
Start Page: 1
End Page: 15
Journal / Book Title: Journal of Biological Chemistry
Volume: 297
Issue: 6
Copyright Statement: © 2021 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Sponsor/Funder: Wellcome Trust ISSF Funding
Medical Research Council
Funder's Grant Number: 204834/Z/16/Z
MC-A654-5QB40
Keywords: MPTP toxicity
Parkinson’s disease
Synuclein
dopamine
dopaminergic neurons
neurodegenerative disease
neurotransmitter vesicular uptake
synapse
transgenic mice
vesicles
MPTP toxicity
Parkinson’s disease
Synuclein
dopamine
dopaminergic neurons
neurodegenerative disease
neurotransmitter vesicular uptake
synapse
transgenic mice
vesicles
03 Chemical Sciences
06 Biological Sciences
11 Medical and Health Sciences
Biochemistry & Molecular Biology
Publication Status: Published
Conference Place: United States
Online Publication Date: 2021-11-02
Appears in Collections:Department of Metabolism, Digestion and Reproduction
Institute of Clinical Sciences



This item is licensed under a Creative Commons License Creative Commons